PepGen (NASDAQ:PEPG) is a clinical‐stage biotechnology company dedicated to advancing peptide nucleic acid (PNA) therapeutics for serious genetic diseases. The company leverages its proprietary conjugation platform to enhance cellular delivery and target engagement of PNA molecules, aiming to address disorders with limited treatment options. Headquartered in San Diego, California, PepGen focuses on precision medicines that modulate gene expression, with a particular emphasis on rare neuromuscular and neurometabolic conditions.
The company’s core activities center on the design, synthesis and development of PNA conjugates engineered for stability, specificity and efficient tissue penetration. PepGen’s lead candidate, PEP-101, is being developed for the treatment of Duchenne muscular dystrophy, while additional pipeline programs target myotonic dystrophy type 1 and other inherited neuromuscular indications. Beyond internal programs, the company has established collaborations with academic institutions and global pharmaceutical partners to expand the application of its PNA platform across multiple therapeutic areas.
PepGen was founded in 2019 by a team of scientists with deep expertise in oligonucleotide chemistry and peptide engineering. Following a successful initial public offering in 2021, the company has grown its research operations in North America and formed partnerships in Europe and Asia to support preclinical and early‐stage clinical development. Its integrated research and development facilities combine medicinal chemistry, in vitro and in vivo pharmacology, and translational biomarker capabilities to accelerate candidate selection and regulatory filings.
The leadership team at PepGen includes Chief Executive Officer Gregory A. Frank, Ph.D., who brings more than two decades of experience in developing nucleic acid therapeutics, and Chief Financial Officer John Kerwin, a biopharma finance veteran. Guided by a board of directors with backgrounds in biotechnology innovation, clinical development and commercial strategy, PepGen continues to build on its mission to deliver novel, peptide‐conjugated therapies that address high‐unmet‐need genetic diseases worldwide.
